Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.

Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR, Ackeifi CA, Rosen J, Pyle L, Snell-Bergeon JK, Shah VN

Diabetes care1 May 2026Cited by 6 (Europe PMC)

PMID41429002PMCIDPMC13094866DOI10.2337/dc25-2249PepBankPUB-41429002

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, semaglutide reduced total daily insulin dose by 22.6% from baseline to week 26.
In plain wordsIn adults with type 1 diabetes and obesity, semaglutide lowered the total daily insulin dose by about a fifth over 26 weeks.
Peptide
Semaglutide
Outcome
DecreaseTotal daily insulin dose reduction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Total daily insulin dose change
−22.6%
semaglutide, week 26
Source sentences
Summary
From baseline to week 26, there was a significant 22.6% reduction in TDD (95% CI -28.3 to -17.0)
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, semaglutide reduced bolus insulin by 30.5%.
In plain wordsIn adults with type 1 diabetes and obesity, semaglutide lowered mealtime insulin doses by 30.5%.
Peptide
Semaglutide
Outcome
DecreaseBolus insulin dose reduction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Bolus insulin change
−30.5%
semaglutide
Source sentences
Summary
greater reductions in bolus insulin (-30.5%; 95% CI -39.5 to -21.5)
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity using automated insulin delivery, semaglutide reduced basal insulin by 15.6%.
In plain wordsIn adults with type 1 diabetes and obesity, semaglutide lowered background insulin doses by 15.6%.
Peptide
Semaglutide
Outcome
DecreaseBasal insulin dose reduction
Study
n: not reported in source
Comparator
Placebo
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Basal insulin change
−15.6%
semaglutide
Source sentences
Summary
than basal insulin (-15.6%; 95% CI -21.5 to -9.7)
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity, the basal-to-total daily dose ratio rose from 0.56 to 0.62 in the semaglutide group.
In plain wordsIn adults with type 1 diabetes and obesity on semaglutide, the share of insulin given as background insulin rose.
Peptide
Semaglutide
Outcome
IncreaseBasal-to-total daily dose ratio
Study
n: not reported in source
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Basal-to-TDD ratio, baseline
0.56 ratio
semaglutide
Basal-to-TDD ratio, follow-up
0.62 ratio
semaglutide
Source sentences
Summary
The basal-to-TDD ratio increased from 0.56 to 0.62 (P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900204
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity, insulin dose per kg fell from 0.72 to 0.60 units/kg/day in the semaglutide group.
In plain wordsIn adults with type 1 diabetes and obesity on semaglutide, the daily insulin dose per kilogram of body weight fell.
Peptide
Semaglutide
Outcome
DecreaseInsulin dose per kg per day
Study
n: not reported in source
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Insulin dose, baseline
0.72 units/kg/day
semaglutide
Insulin dose, follow-up
0.6 units/kg/day
semaglutide
Source sentences
Summary
insulin dose (in units/kg/day) decreased from 0.72 to 0.60 (P < 0.001) in the semaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900205
06HumanRandomized controlled trialMechanism
In adults with type 1 diabetes and obesity, 83% of the week 4 reduction in total daily insulin dose was a direct semaglutide effect and 17% was attributed to weight loss.
In plain wordsIn adults with type 1 diabetes and obesity, most early insulin reduction on semaglutide came from the drug itself, not from weight loss.
Peptide
Semaglutide
Outcome
Not applicableDirect drug effect versus weight loss in insulin reduction, week 4
Study
n: not reported in source
Comparator
Placebo
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Direct effect share
83%
week 4
Weight-loss share
17%
week 4
Source sentences
Summary
At week 4, an 83% (-11.1 units/day) reduction in TDD was due to a direct drug effect, and 17% (-2.3 units/day) was attributed to weight loss
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900206
07HumanRandomized controlled trialMechanism
In adults with type 1 diabetes and obesity, at week 26 the insulin reduction was split between a direct semaglutide effect (52%) and weight loss (48%).
In plain wordsIn adults with type 1 diabetes and obesity, at 26 weeks the insulin reduction came about equally from semaglutide itself and from weight loss.
Peptide
Semaglutide
Outcome
Not applicableDirect drug effect versus weight loss in insulin reduction, week 26
Study
n: not reported in source
Comparator
Placebo
Outcome group
Patterns of use · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Direct effect share
52%
week 26
Weight-loss share
48%
week 26
Source sentences
Summary
whereas at week 26, the difference was split evenly between direct effect (-11.4 units/day; 52%) and weight loss (-10.5 units/day; 48%)
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900207
08HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and obesity, daily carbohydrate intake decreased from 137 g at baseline to 107 g at 26 weeks.
In plain wordsIn adults with type 1 diabetes and obesity, daily carbohydrate intake fell over 26 weeks.
Peptide
Semaglutide
Outcome
DecreaseDaily carbohydrate intake
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1 mg/week · 26 weeksAs given in this study (human).
Measurements
Daily carbohydrate intake, baseline
137 g
baseline
Daily carbohydrate intake, follow-up
107 g
26 weeks
Source sentences
Summary
Daily carbohydrate intake decreased from 137 g (95% CI 107-167) at baseline to 107 g (95% CI 76-137) at 26 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In this post hoc analysis, we used the data from the Adjunct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) trial, a double-blind, multicenter, randomized, placebo-controlled trial of semaglutide 1 mg/week in adults with type 1 diabetes (T1D) and obesity, to evaluate the relationship between…
Summary · context
Changes between semaglutide and placebo groups over 26 weeks in total daily insulin dose (TDD), basal and bolus insulin doses, carbohydrate intake, and user-initiated bolus counts were analyzed using linear mixed models.
Report a problemFND-4142900208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.